Genetic acute myeloid leukemia

Raponi M, Belly RT, Karp JE, Lancet JE, Atkins D, Wang Y. Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia. BMC Cancer 2004 4 56. 

Crowley JA, Wang Y, Rapoport AP, Ning Y (2005) Detection of MOZ-CBP fusion in acute myeloid leukemia with 8 16 translocation. Leukemia 19 2344-2345 Dash A, Gilliland DG (2001) Molecular genetics of acute myeloid leukaemia. Best Pract Res Clin Haematol 14 49-64... 

Hayashi Y (2000) The molecular genetics of recurring chromosome abnormalities in acute myeloid leukemia [In Process Citation]. Semin Hematol 37 368-380 Heery DM, Kalkhoven E, Hoare S, Parker MG (1997) A signature motif in transcriptional co-activators mediates binding to nuclear receptors [see comments]. Nature 387 733-736 Ida K, Kitabayashi I, Taki T, Taniwaki M, Noro K, Yamamoto M, Ohki M, Hayashi Y (1997) Adenoviral E 1 A-associated protein p300 is involved in acute myeloid leukemia with t(ll 22)(q23 ql3). Blood 90 4699-4704... 

Pedersen-Bjergaard J, Andersen MK, Christiansen DH, Nerlov C. Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood 2002 99 1909-12. 

Pedersen-Bjergaard J, Philip P. Two different classes of therapy-related and de-novo acute myeloid leukemia Cancer Genet Cytogenet 1991 55(l) 119-24. 

Acute myeloid leukemia (AML) with recurrent genetic abnormalities AML with t(8 21)(q22 q22), (AML1/ETO)... 

Archimbaud E, Thomas X, Michallet M, et al. Prospective genetically randomized comparison between intensive post-induction chemotherapy and bone marrow transplantation in adults with newly diagnosed acute myeloid leukemia. J Qin Oncol 1994 12 262-267. 

Somatic mutations in PTPNll in juvenile myelomonocytic leukemia, myelodys-plastic syndromes and acute myeloid leukemia. Nat Genet 34 148-150... 

Advice for treatment decisions based on specific genetic conditions were found in four Pis, namely that prolastin (a 1-proteinase inhibitor) is not indicated in patients with certain otl -antitrypsin deficiency phenotypes, trastuzumab indicated only in patients with overexpression of the HER2 protein, tretinoin, and imatinib are to be given only in patients with either a specific subtype of acute myelogenous leukemia or Philadelphia chromosome-positive chronic myeloid leukemia, respectively. 

Genetics has already been incorporated into the care of children with cancer an example is the Philadelphia Chromosome, a chromosomal anomaly produced as a result of reciprocal translocation between chromosomes 9 and 22 [t(9 22)(q34 qll)] that is most commonly seen as a marker of chronic myeloid leukemia [50]. The presence of this chromosomal anomaly is associated with altered prognosis—and the need for different therapy—when seen in the context of acute lymphoblastic leukemia in childhood [51], An area of oncology care where genetics has not been widely used has been in the evaluation—and possibly prevention—of adverse drug reactions [52],... 

---